KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Amortization - Intangibles (2021 - 2026)

Pacific Biosciences Of California has reported Amortization - Intangibles over the past 5 years, most recently at $833000.0 for Q4 2025.

  • For Q4 2025, Amortization - Intangibles rose 120.91% year-over-year to $833000.0; the TTM value through Dec 2025 reached $6.2 million, down 30.75%, while the annual FY2025 figure was $364.5 million, 3780.99% up from the prior year.
  • Amortization - Intangibles for Q4 2025 was $833000.0 at Pacific Biosciences Of California, up from $183000.0 in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $5.5 million in Q1 2024 and troughed at -$4.0 million in Q4 2024.
  • A 5-year average of $1.5 million and a median of $741000.0 in 2023 define the central range for Amortization - Intangibles.
  • On a YoY basis, Amortization - Intangibles climbed as much as 2908.74% in 2024 and fell as far as 173.56% in 2024.
  • Year by year, Amortization - Intangibles stood at -$123000.0 in 2021, then surged by 248.78% to $183000.0 in 2022, then soared by 2859.56% to $5.4 million in 2023, then plummeted by 173.56% to -$4.0 million in 2024, then surged by 120.91% to $833000.0 in 2025.
  • Business Quant data shows Amortization - Intangibles for PACB at $833000.0 in Q4 2025, $183000.0 in Q3 2025, and $833000.0 in Q2 2025.